Reserpine-d9

• UNSPSC Description:

  Reserpine-d9 is the deuterium labeled Reserpine. Reserpine is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).

• Target Antigen:

  Autophagy; Isotope-Labeled Compounds; Monoamine Transporter

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Membrane Transporter/Ion Channel;Others

• Field of Research:

  Neurological Disease; Cancer

• Purity:

  97.0

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles:

  COC([C@H]1[C@@]2([H])C[C@]3([H])C4=C(CCN3C[C@@]2([H])C[C@H]([C@@H]1OC)OC(C5=CC(OC([2H])([2H])[2H])=C(C(OC([2H])([2H])[2H])=C5)OC([2H])([2H])[2H])=O)C6=CC=C(OC)C=C6N4)=O

• Molecular Weight:

  617.73

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Antkiewicz-Michaluk L, et al. Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: a behavioral and neurochemical ex vivo and in vivo studies in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:146-54.|[3]Hong B, et al. Reserpine Inhibit the JB6 P+ Cell Transformation Through Epigenetic Reactivation of Nrf2-Mediated Anti-oxidative Stress Pathway. AAPS J. 2016 May;18(3):659-69.|[4]Sreemantula S, et al. Reserpine methonitrate, a novel quaternary analogue of reserpine augments urinary excretion of VMA and 5-HIAA without affecting HVA in rats. BMC Pharmacol. 2004 Nov 16;4:30.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  84759-11-5